GRP78 Antibodies Are Associated With Blood-Brain Barrier Breakdown in Anti–Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disorder
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received January 11, 2021
- Accepted in final form May 25, 2021
- First Published November 1, 2021.
Author Disclosures
- Fumitaka Shimizu, MD, PhD (fshimizu{at}yamaguchi-u.ac.jp),
- Ryo Ogawa, MD, PhD (ryo38092001{at}yahoo.co.jp),
- Yoichi Mizukami, MD, PhD (mizukami{at}yamaguchi-u.ac.jp),
- Kenji Watanabe, PhD (wataken{at}yamaguchi-u.ac.jp),
- Kanako Hara (v078eb{at}yamaguchi-u.ac.jp),
- Chihiro Kadono (g024eb{at}yamaguchi-u.ac.jp),
- Toshiyuki Takahashi, MD, PhD (t-toshiyuki{at}mta.biglobe.ne.jp),
- Tatsuro Misu, MD, PhD (misu{at}med.tohoku.ac.jp),
- Yukio Takeshita, MD, PhD (takeshy{at}yamaguchi-u.ac.jp),
- Yasuteru Sano, MD, PhD (yasuteru{at}yamaguchi-u.ac.jp),
- Miwako Fujisawa, MD (fuji0418{at}yamaguchi-u.ac.jp),
- Toshihiko Maeda, MD, PhD,
- Ichiro Nakashima, MD, PhD (nakashima{at}tohoku-mpu.ac.jp),
- Kazuo Fujihara, MD, PhD (fujikazu{at}med.tohoku.ac.jp) and
- Takashi Kanda, MD, PhD
- Fumitaka Shimizu, MD, PhD (fshimizu{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, postdoctoral scientist, 1 years 10 month(2014.11- 2016.8)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ryo Ogawa, MD, PhD (ryo38092001{at}yahoo.co.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yoichi Mizukami, MD, PhD (mizukami{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kenji Watanabe, PhD (wataken{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kanako Hara (v078eb{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Chihiro Kadono (g024eb{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Toshiyuki Takahashi, MD, PhD (t-toshiyuki{at}mta.biglobe.ne.jp),
NONE
NONE
Cosmic corporation, speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1)Cosmic corporation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Tatsuro Misu, MD, PhD (misu{at}med.tohoku.ac.jp),
NONE
NONE
Speaker honoraria from Novartis Pharma, Tanabe-Mitsubishi Pharma, Biogen Idec Japan, Teijin Pharma, Chugai Pharma, Alexion Pharma, and Viela Bio.
Frontiers in Neurology/Immunology, Associate editor, 2020-21
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Research support from Cosmic Corporation.
NONE
NONE
Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labor and Welfare of Japan.
NONE
NONE
NONE
NONE
NONE
NONE
- Yukio Takeshita, MD, PhD (takeshy{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Yasuteru Sano, MD, PhD (yasuteru{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Miwako Fujisawa, MD (fuji0418{at}yamaguchi-u.ac.jp),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Toshihiko Maeda, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ichiro Nakashima, MD, PhD (nakashima{at}tohoku-mpu.ac.jp),
NONE
NONE
(1) Alexion Pharma, travel and speaker honoraria (2) Biogen Japan, advisory fee, travel and speaker honoraria (3) Novartis Pharma, travel and speaker honoraria (4) Chugai Pharmaceutical, travel and speaker honoraria
NONE
NONE
NONE
NONE
(1) Alexion Pharma (2) Biogen Japan (3) Novartis Pharma (4) Chugai Pharmaceutical
NONE
NONE
NONE
(1)LSI Medience Corporation
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Kazuo Fujihara, MD, PhD (fujikazu{at}med.tohoku.ac.jp) and
Serves on scientific advisory boards for Biogen, Mitsubishi-Tanabe, Novartis, Chugai, Alexion, VielaBio, UCB and Abbvie.
NONE
has received funding for travel or speaker honoraria from Chugai, Roche, Biogen, Novartis, Alexion, Alexion, Teijin, Mitsubishi-Tanabe, AsahiKasei, Merck, Eisai and Bayer.
Serve as an editorial board member of Clinical and Experimental Neuroimmunology (2009-present), Frontiers in Neurology (2017-present), Neurology: Neuroimmunology and Neuroinflammation (2018-present), Multiple Sclerosis (2019- present), Multiple Sclerosis and Related Disorders (2020- present) and Neuroimmunology Reports (2021-present) and advisory board member of Sri Lanka journal of Neurology.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
funded as the investigator (2010Â2020) by the Grants- in-Aid for Scientific Research from the Ministry of Education, Science and Technology of Japan and as the secondary investigator by the Grants-in-Aid for Scientific Research from the Ministry of Health, Welfare and Labor of Japan (2010Âpresent).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Takashi Kanda, MD, PhD
(1) CSL Behring (2) Chugai Paharmaceutical Co.
NONE
(1) Novartis Pharma Co, speaker honararia (2) Otsuka Pharmaceutical, speaker honararia (3) Ayumi Pharmaceutical, speaker honararia (4) Japan Blood, speaker honararia (5) Takeda Pharmacuetical Co., speaker honararia (6) Kyowa-Kirin Pharmaceutical Co., speaker honararia (7) Dainipponsumitomo Pharmaceutical Co., speaker honararia (8) Tanabe Mitsubishi Pharmaceutical Co., speaker honararia (9) CSL Behring,, speaker honararia (10) Janssen Pahrmaceutical Co., speaker honararia (11) Teijin Pharm., speaker honararia (12) Biogen Japan, speaker honararia (13) Eosai Pharmaceutical, speaker honararia (14) Alexion Pharm., speaker honararia (15) Glaxo Smith Klein, , speaker honararia (16) Ono Pharmaceutical Co., speaker honararia
(1) Clinical and Experimental Neuroimmunology Editor-in- Chief 2010-2018 (2) Neuropathology, Editorial Advisory Board Member 2009- (3) Brain and Nerve Editor-in-Chief 2018- (4) Peripheral Nerve, Editor-in-Chief, 2017- (5) Fluids and Barriers of the CNS, Editor 2014-
(1) in vitro model of blood-brain barrier
NONE
NONE
(1) Teijin pharmaceutical Co.
NONE
NONE
NONE
(1) Novartis Pharm. (2) Daiichi-Sankyo Co. (3) Asteras Co.
(1) Contract Grant Sponsor: Japan Society for the Promotion of Science - Tokyo Contract Grant Number: 25293203, 26670443, 17H04197
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine (F.S., K.H., C.K., Y.T., Y.S., M.F., T. Maeda, T.K.), Ube; Department of Neurology, Tohoku University Graduate School of Medicine (R.O., T.T., T. Misu), Sendai; Center for Gene Research (Y.M., K.W.), Yamaguchi University (Y.M., K.W.), Ube; Department of Neurology, National Hospital Organization Yonezawa Hospital (T.T.); Department of Neurology, Tohoku Medical and Pharmaceutical University (I.N.), Sendai; and Department of Multiple Sclerosis Therapeutics, Fukushima Medical University (K.F.), Japan.
- Correspondence
Dr. Kanda tkanda{at}yamaguchi-u.ac.jp
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.